Platinum Investment Management Ltd. Raises Stake in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Platinum Investment Management Ltd. raised its stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 8.6% during the second quarter, Holdings Channel reports. The fund owned 290,836 shares of the company’s stock after buying an additional 22,949 shares during the period. Platinum Investment Management Ltd.’s holdings in Centessa Pharmaceuticals were worth $3,822,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Trexquant Investment LP lifted its stake in Centessa Pharmaceuticals by 1.1% in the first quarter. Trexquant Investment LP now owns 263,994 shares of the company’s stock valued at $3,796,000 after purchasing an additional 2,810 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of Centessa Pharmaceuticals by 15,209.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock valued at $46,000 after buying an additional 3,194 shares during the last quarter. Osterweis Capital Management Inc. purchased a new position in shares of Centessa Pharmaceuticals during the 1st quarter valued at $47,000. Exome Asset Management LLC lifted its position in shares of Centessa Pharmaceuticals by 3.7% during the 1st quarter. Exome Asset Management LLC now owns 142,744 shares of the company’s stock valued at $2,053,000 after buying an additional 5,028 shares during the last quarter. Finally, Lord Abbett & CO. LLC lifted its holdings in Centessa Pharmaceuticals by 1.3% during the first quarter. Lord Abbett & CO. LLC now owns 446,196 shares of the company’s stock valued at $6,416,000 after purchasing an additional 5,701 shares during the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Trading Down 6.7%

Shares of CNTA stock opened at $22.62 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 10.12 and a current ratio of 10.11. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $9.60 and a 52-week high of $24.57. The company has a market capitalization of $3.03 billion, a PE ratio of -12.64 and a beta of 1.56. The business’s fifty day moving average is $18.81 and its 200 day moving average is $15.24.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). On average, equities research analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CTO Tia L. Bush sold 35,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $24.00, for a total transaction of $840,000.00. Following the completion of the sale, the chief technology officer directly owned 121,503 shares in the company, valued at $2,916,072. The trade was a 22.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $15.56, for a total transaction of $155,600.00. Following the sale, the insider owned 122,279 shares of the company’s stock, valued at approximately $1,902,661.24. The trade was a 7.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 205,286 shares of company stock valued at $3,993,345. Company insiders own 7.09% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on CNTA. Wall Street Zen downgraded shares of Centessa Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a research note on Friday, August 29th. They set an “outperform” rating and a $40.00 price target on the stock. Truist Financial began coverage on Centessa Pharmaceuticals in a research report on Monday, July 21st. They set a “buy” rating and a $30.00 target price on the stock. Wells Fargo & Company initiated coverage on Centessa Pharmaceuticals in a research report on Wednesday, September 3rd. They set an “overweight” rating and a $31.00 target price on the stock. Finally, Chardan Capital reissued a “buy” rating and set a $30.00 price objective on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating and nine have issued a Buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $32.38.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.